The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells through...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1826305777108779008 |
|---|---|
| author | Grozinsky-Glasberg, S Grossman, AB Korbonits, M |
| author_facet | Grozinsky-Glasberg, S Grossman, AB Korbonits, M |
| author_sort | Grozinsky-Glasberg, S |
| collection | OXFORD |
| description | Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells throughout the digestive or respiratory tracts. The clinical behaviour of neuroendocrine tumours is variable; they may be functioning or not functioning, ranging from well-differentiated slow growing neuroendocrine tumours to poorly differentiated neuroendocrine tumours, which are highly aggressive malignant tumours. The development of somatostatin analogues as important diagnostic and treatment tools have revolutionised the clinical management of patients with neuroendocrine tumours. However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with somatostatin analogues, tumour regression is rare. Development of new somatostatin analogues and new drug combination therapies should further improve the clinical management of these patients. |
| first_indexed | 2024-03-07T06:37:59Z |
| format | Journal article |
| id | oxford-uuid:f84fc65c-a163-4b2a-95de-9b0bca258cfb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:37:59Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:f84fc65c-a163-4b2a-95de-9b0bca258cfb2022-03-27T12:49:19ZThe role of somatostatin analogues in the treatment of neuroendocrine tumours.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f84fc65c-a163-4b2a-95de-9b0bca258cfbEnglishSymplectic Elements at Oxford2008Grozinsky-Glasberg, SGrossman, ABKorbonits, MNeuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells throughout the digestive or respiratory tracts. The clinical behaviour of neuroendocrine tumours is variable; they may be functioning or not functioning, ranging from well-differentiated slow growing neuroendocrine tumours to poorly differentiated neuroendocrine tumours, which are highly aggressive malignant tumours. The development of somatostatin analogues as important diagnostic and treatment tools have revolutionised the clinical management of patients with neuroendocrine tumours. However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with somatostatin analogues, tumour regression is rare. Development of new somatostatin analogues and new drug combination therapies should further improve the clinical management of these patients. |
| spellingShingle | Grozinsky-Glasberg, S Grossman, AB Korbonits, M The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title | The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title_full | The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title_fullStr | The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title_full_unstemmed | The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title_short | The role of somatostatin analogues in the treatment of neuroendocrine tumours. |
| title_sort | role of somatostatin analogues in the treatment of neuroendocrine tumours |
| work_keys_str_mv | AT grozinskyglasbergs theroleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours AT grossmanab theroleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours AT korbonitsm theroleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours AT grozinskyglasbergs roleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours AT grossmanab roleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours AT korbonitsm roleofsomatostatinanaloguesinthetreatmentofneuroendocrinetumours |